



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/646,391 | |
| | | | Filing Date | 8/21/2003 | |
| | | | First Named Inventor | Gleave et al. | |
| | | | Art Unit | 2511/035 | |
| | | | Examiner Name | Bowman | |
| Sheet | 1 | of | 4 | Attorney Docket Number | UBC.P-035 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| ams | | US-5,646,042 | 07-08-1997 | Stinchcomb et al. | |
| | | US-5,789,389 | 08-04-1998 | Tarasewicz et al. | |
| | | US-5,929,040 | 07-27-1999 | Werther et al. | |
| | | US-5,998,148 | 12-07-1999 | Bennet et al. | |
| | | US-6,172,216 B1 | 01-09-2001 | Bennett et al. | |
| | | US-6,335,194 B1 | 01-01-2002 | Bennett et al. | |
| | | US-6,383,808 B1 | 05-07-2002 | Monia et al. | |
| | | US-2003/0158130 A1 | 08-21-2003 | Gleave et al. | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ - Kind Code ⁵ (# known) | | | | |
| ams ↓ | | WO 00/34469 | 06-15-2000 | The Research Foundation of | | |
| | | WO 00/49937 | 08-31-2000 | The University of British | | |
| | | WO 01/46455 A2 | 06-28-2001 | Yale University | | |
| | | WO 02/22635 A1 | 03-21-2002 | ISIS Pharmaceuticals, Inc. | | |
| | | WO 03/062421 A1 | 07-31-2003 | The University of British | | |
| | | WO 03/072591 A1 | 09-04-2003 | The University of British | | |
| | | WO 2004/018675 A1 | 03-04-2004 | The University of British | | |
| | | WO 2004/018676 A2 | 03-04-2004 | The University of British | | |
| | | | | | | |
| | | | | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 8/29/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|---------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/646,391 |
| | | Filing Date | 8/21/2003 |
| | | First Named Inventor | Gleave et al. |
| | | Art Unit | 4614/1038 |
| | | Examiner Name | Burnan |
| Sheet 2 of 4 | Attorney Docket Number | UBC-P-035 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| ATB | | AGRAWAL ET AL., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, Page(s) 72-81, Volume 6, Publisher: Elsevier Science Ltd. | |
| | | AOKI ET AL., RNA Interference may be more potent than antisense RNA in human cancer cell lines, Clinical and Experimental Pharmacology and Physiology, 2003, Page(s) 96-102 | |
| | | BENNER ET AL., Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies, Journal of Pharmacological and Toxicological Methods, 1997, Page(s) 229-235, Publisher: Elsevier Science Inc. | |
| | | BORAL ET AL., Clinical evaluation of biologically targeted drugs: obstacles and opportunities, Cancer Chemother Pharmacol, 1998, Page(s) S3-S21, Publisher: Springer-Verlag | |
| | | ANDREA D. BRANCH, A good antisense molecule is hard to find, TIBS, 1998, Page(s) 45-50, Publisher: Elsevier Science Ltd. | |
| | | STEVEN BREM, MD, Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Cancer Control Journal, 1999, Volume 6, Number 5, Publisher: H. Lee Moffitt Cancer Center & Research Institute | |
| | | BRUCHOVSKY ET AL., Control of Tumor Progression by Maintenance of Apoptosis, www.prostatepointers.org, 1996, Publisher: Wiley-Liss, Inc. | |
| | | BUTTYAN ET AL., Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death, Molecular and Cellular Biology, 1989, Page(s) 3473-3481, Volume 9, Number 8, Publisher: American Society for Microbiology | |
| | | COX ET AL., Angiogenesis and non-small cell lung cancer, Lung Cancer, 2000, Page(s) 81-100, Publisher: Elsevier | |
| | | CROOKE ET AL., Basic principles of antisense therapeutics, Antisense Research and Application, 2004, Page(s) 1-50, Chapter 1, Publisher: Springer | |
| ✓ | | DARBY ET AL., Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity, Exp Nephrol, 1995, Page(s) 234-239, Publisher: S. Karger AG | |

| | | | |
|--------------------|------------|-----------------|---------|
| Examiner Signature | <i>ATB</i> | Date Considered | 8/29/03 |
|--------------------|------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|---------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/646,391 |
| | | | | Filing Date | 8/21/2003 |
| | | | | First Named Inventor | Gleave et al. |
| | | | | Art Unit | 1614 1035 |
| | | | | Examiner Name | Bowman |
| Sheet | 3 | of | 4 | Attorney Docket Number | UBC.P-035 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AMB | | DIEMER ET AL., Expression of Porcine Complement Cytolysis Inhibitor mRNA in Cultured Aortic Smooth Muscle Cells, The Journal of Biological Chemistry, March 15, 1992, Page(s) 5257-5264, Volume 207, Number 8, Publisher: The American Society for Biochemistry and Molecular Biology, Inc. | |
| | | GENTA, New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment, www.genta.com, 2001 | |
| | | JEN ET AL., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells 2000, 2000, Page(s) 307-319, Volume 18 | |
| | | KADOMATSU ET AL., Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate..., Cancer Res, April 1, 1993, Page(s) 1480-1483, Volume 53, Number 7 | |
| | | KIRBY ET AL., Bartonella-associated endothelial proliferation depends on inhibition of apoptosis, PNAS, April 2, 2002, Page(s) 4656-4661, Volume 99, Number 7 | |
| | | KYPRIANOU ET AL., bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate, International Journal of Cancer, January 27, 1997, Page(s) 341-348, Volume 70, Number 3 | |
| | | LEE ET AL., In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator, The Prostate Supplement, 2000, Page(s) 21-24, Volume 9, Publisher: Wiley-Liss, Inc. | |
| | | MILLAR ET AL., Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous, International Journal of Andrology, 1994, Page(s) 149-160, Volume 17 | |
| | | MILLIS ET AL., Clusterin Regulates Vascular Smooth Muscle Cell Nodule Formation and Migration, Journal of Cellular Physiology, 2001, Page(s) 210-219, Volume 186, Publisher: Wiley-Liss, Inc. | |
| | | MILNER ET AL., Selecting effective antisense reagents on combinatorial oligonucleotide arrays, Nature Biotechnology, 1997, Page(s) 537-541, Volume 15 | |
| | | NOR ET AL., Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice, Laboratory Investigation, 2001, Page(s) 453-463, Volume 81, Number 4 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 8/29/05 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|---------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/646,391 |
| | | Filing Date | 8/21/2003 |
| | | First Named Inventor | Gleave et al. |
| | | Art Unit | 1814 1835 |
| | | Examiner Name | Bowman |
| Sheet 4 of 4 | Attorney Docket Number | UBC.P-035 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| AMB | | NÖR ET AL., Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; March 1, 2001, Page(s) 2183-2188, Volume 61 | |
| | | OPALINSKA ET AL., Nucleic-acid therapeutics: Basic principles and recent applications, Nature Reviews, 2002, Page(s) 503-514, Volume 1 | |
| | | TRAN ET AL., A role for survivin in chemoresistance of endothelial cells mediated by VEGF, PNAS, April 2, 2002, Page(s) 4349-4354, Volume 99, Number 7 | |
| | | TROUGAKOS ET AL., Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces, Cancer Research, March 1, 2004, Page(s) 1834-1842, Volume 64 | |
| | | VICKERS ET AL., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, The Journal of Biological Chemistry, February 28, 2003, Page(s) 7103-7118, Volume 278, Number 9 | |
| | | WRIGHT ET AL., A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate, Experimental Cell Research, January 10, 1996, Page(s) 54-60, Volume 222, Number 1 | |
| | | YANG ET AL., Nuclear clusterin/XIPB, an x-ray-induced Ku70-binding protein that signals cell death, PNAS, May 23, 2000, Page(s) 5907-5912, Volume 97, Number 11 | |
| | | ZWAIN ET AL., Clusterin Protects Granulosa Cells from Apoptotic Cell Death during Follicular Atresia, Experimental Cell Research, 2000, Page(s) 101-110, Volume 257, Publisher: Academic Press | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 8/29/05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.